Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Change in Accured Expenses: 2017-2022

Historic Change in Accured Expenses for Arcus Biosciences (RCUS) over the last 6 years, with Sep 2022 value amounting to $23.5 million.

  • Arcus Biosciences' Change in Accured Expenses rose 169.22% to $23.5 million in Q3 2022 from the same period last year, while for Sep 2022 it was $4.2 million, marking a year-over-year decrease of 54.35%. This contributed to the annual value of $10.1 million for FY2021, which is 26.19% down from last year.
  • Arcus Biosciences' Change in Accured Expenses amounted to $23.5 million in Q3 2022, which was up 1,434.47% from -$1.8 million recorded in Q2 2022.
  • In the past 5 years, Arcus Biosciences' Change in Accured Expenses ranged from a high of $23.5 million in Q3 2022 and a low of -$9.9 million during Q4 2020.
  • For the 3-year period, Arcus Biosciences' Change in Accured Expenses averaged around $3.4 million, with its median value being $4.7 million (2021).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first spiked by 1,209.05% in 2018, then slumped by 705.35% in 2020.
  • Quarterly analysis of 5 years shows Arcus Biosciences' Change in Accured Expenses stood at -$2.3 million in 2018, then soared by 45.61% to -$1.2 million in 2019, then tumbled by 705.35% to -$9.9 million in 2020, then climbed by 9.11% to -$9.0 million in 2021, then spiked by 169.22% to $23.5 million in 2022.
  • Its last three reported values are $23.5 million in Q3 2022, -$1.8 million for Q2 2022, and -$8.5 million during Q1 2022.